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Biodistribution and Pharmacokinetics Study of 
siRNA-loaded Anti-NTSR1-mAb-functionalized Novel
Hybrid Nanoparticles in a Metastatic Orthotopic Murine
Lung Cancer Model
Maryna Perepelyuk1, Chellappagounder Thangavel2, Yi Liu2, Robert B Den2, Bo Lu2, Adam E Snook3 and Sunday A Shoyele1

Small interfering RNA (siRNA) is effective in silencing critical molecular pathways in cancer. The use of this tool as a treatment
modality is limited by lack of an intelligent carrier system to enhance the preferential delivery of this molecule to specific targets
in vivo. In the present study, the in vivo behavior of novel anti-NTSR1-mAb-functionalized antimutant K-ras siRNA-loaded
hybrid nanoparticles, delivered by i.p. injection to non-small-cell lung cancer in mice models, was investigated and compared
to that of a naked siRNA formulation. The siRNA in anti-NTSR1-mAb-functionalized hybrid nanoparticles was preferentially
accumulated in tumor-bearing lungs and metastasized tumor for at least 48 hours while the naked siRNA formulation showed
lack of preferential accumulation in all of the organs monitored. The plasma terminal half-life of nanoparticle-delivered siRNA
was 11 times higher (17–1.5 hours) than that of the naked siRNA formulation. The mean residence time and AUClast were 3.4
and 33 times higher than the corresponding naked siRNA formulation, respectively. High-performance liquid chromatography
analysis showed that the hybrid nanoparticle carrier system protected the encapsulated siRNA against degradation in vivo.
Our novel anti-NTSR1-mAb-functionalized hybrid nanoparticles provide a useful platform for in vivo targeting of siRNA for both
experimental and clinical purposes.
Molecular Therapy—Nucleic Acids (2016) 5, e282; doi:10.1038/mtna.2015.56; published online 26 January 2016
Subject Category: Nanoparticles; Therapeutic proof-of-concept

Introduction
Small interfering RNAs (siRNAs) have emerged as molecules
with high potential to silence critical molecular pathways
involved in tumor progression. However, to harness the full
potential of this treatment modality in the clinical arena, intelligent nanoparticle delivery systems need to be developed
in tandem. This is crucial since siRNAs have been shown to
lack the capacity to be transfected into cells on their own due
to their relatively high polarity and molecular size.1 To deliver
siRNA to an intracellular target, a nanoparticle delivery system is often used to “mask” the negative charges on these
molecules. The small size of these nanoparticles facilitates
endocytosis, enabling the internalization of siRNAs while preventing degradation within the lysosomes.2 Naked (unencapsulated) siRNA are also degraded by serum endonucleases
and efficiently cleared from systemic circulation by glomerular filtration, resulting in a very short plasma half-life.3,4 Various carriers have been studied as potential delivery vehicles
for siRNA therapeutic. Such carriers include cell-penetrating
peptides, lipid-based carriers, and polymeric and dendrimeric
carriers.1,5,6 However, these delivery systems are still limited
by major challenges.4 Therefore, there is an unmet need for
a smart nanoparticle delivery system for efficient and stable
siRNA transfection.

Recently, our group reported on a novel hybrid nanoparticle delivery system for siRNA delivery. These nanoparticles,
composed of human IgG and poloxamer-188, are designed
to prevent immunogenic/inflammatory response in vivo and
to reduce clearance by macrophages. These nanoparticles
were able to successfully deliver siRNA to the cytosol of A549
lung cancer cell lines without eliciting immunogenic/inflammatory response in murine macrophages, RAW 264.7.4,7
Using these nanoparticles to deliver siRNA against mutant
K-ras, a significant downregulation of both protein and mRNA
of K-ras was achieved.4 Further, the enclosed siRNA was
protected from nuclease in 50% serum for up to 48 hours.
The objective of the current study is to investigate the
potential of these nanoparticles to selectively deliver the
encapsulated siRNA to lung tumor in metastatic orthotopic
murine models of non-small-cell lung cancer (NSCLC), following the functionalization of the nanoparticles with antineurotensin receptor 1 monoclonal antibody (anti-NTSR1-mAb).
We also aim to determine the pharmacokinetic parameters
of the encapsulated siRNA (antimutant K-ras siRNA) in
comparison to the naked siRNA. NTSR1 is being used as
a target for delivery of these nanoparticles to lung tumor
because NTSR1 has been shown by immunohistochemistry
to be overexpressed in ~60% of lung adenocarcinoma.8 In
early stages of NSCLC, NTSR1 was one of the first 50 genes
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nanoparticles did not demonstrate any antiproliferative effect
in A549 cells (Figure 1c).

upregulated and associated with disease-free survival.8 We
hypothesize that this overexpression in NSCLC can be used
to achieve an optimized targeting of siRNA to NSCLC by
conjugating anti-NTSR1-mAb to the surface of our hybrid
nanoparticles.

Metastatic orthotopic murine model of NSCLC
Mouse models used for these were developed over a 3-week
period. Following the injection of A549-luciferase cells into
the tail vein of the mice, tumor burden was monitored using
Xenogen IVIS bioluminescence imaging system. Tumor was
initially established in the colorectal region after the first
week. This tumor quickly metastasizes to the two lungs of the
mice after 3 weeks of injection as seen in Figure 2.

Results
Nanoparticle preparation, characterization, and in vitro
assessment
Table 1 shows that the nanoparticles were ~135 nm in diameter and the functionalization of these nanoparticles with antiNTSR1-mAb slightly increased the size of the nanoparticles
to 140 nm. Prior to the functionalization of the nanoparticles,
a zeta potential of +16.7 mV was recorded. However, the
nanoparticles showed no charges following the functionalization step. The encapsulation efficiency and loading capacity
of antimutant K-ras siRNA in these nanoparticles were 60
and 2%, respectively.
Scanning electron micrograph of the nanoparticles in
Figure 1a confirms that the nanoparticles were mostly
spherical in shape. The particles were fairly homogenous in
morphology.
Figure 1b demonstrates the knockdown efficiency of these
antimutant K-ras siRNA-loaded hybrid nanoparticles against
G12S mutant K-ras normally expressed in A549 cells. These
nanoparticles produced superior downregulation of G12S
mutant K-ras when compared to lipofectamine 2000 as a
transfection reagent.
Antiproliferative effect of these antimutant K-ras siRNAloaded nanoparticles in A549 cells is further demonstrated
in Figure 1c. In contrast, scramble siRNA-loaded hybrid

Plasma pharmacokinetics
Antimutant K-ras siRNA was isolated from mice plasma using
the analytical procedure described in Figure 6. Ion-pair highperformance liquid chromatography (HPLC) analysis showed
a linear standard curve ranging from 50 to 50,000 ng/ml
(r = 0.9998). The lowest detection limit was 50 ng/ml. siRNA
recovery from plasma following isolation with Clarity OTX
isolation and ion-pair HPLC analysis was consistently above
90%.
Figure 3 demonstrates the plasma concentration versus
time curves when equivalent of 0.9 mg/kg of siRNA either
naked or loaded into anti-NTSR1-mAb-functionalized hybrid
nanoparticles. The maximum concentration (Cmax) of siRNA
delivered by anti-NTSR1-mAb-functionalized hybrid nanoparticles was 17289.5 ng/ml compared to 7504.9 ng/ml observed
for the naked siRNA formulation. These maximum concentrations were observed at 30 and 60 minutes (Tmax) for naked
siRNA and siRNA in anti-NTSR1-mAb-functionalized hybrid
nanoparticles, respectively. Figure 4 demonstrates the superiority of using novel anti-NTSR1-mAb-functionalized hybrid

Table 1 Particle size, PDI, and zeta potential analysis of nanoparticles measured by photon correlation spectroscopy
Particle
size (nm)

PDI

Nanoparticles

135.4 ± 5.4

0.07 ± 0.03

+16.7 ± 0.2

Nanoparticles-anti-NTSR1-mAb

140.2 ± 2.4

0.2 ± 0.04

0.0 ± 0.3

Nanoparticle batch

Zeta
potential (mV)

Encapsulation
efficiency (%)

Loading
capacity (%)

60 ± 0.4

2.04 ± 0.06

N/A

N/A

N/A, not applicable; PDI, polydispersity index.
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Figure 1 Nanoparticle characterization and knockdown efficiency. (a) Scanning electron micrograph shows the spherical morphology
of the nanoparticles. (b) Western blot analysis showing in vitro knockdown efficiency of siRNA nanoparticles against mutant G12S K-ras in
A549 cells. Nano K-ras represents antimutant K-ras siRNA-loaded hybrid nanoparticles, naked K-ras represents unencapsulated antimutant
K-ras siRNA, Nano Scr represents scramble siRNA-loaded hybrid nanoparticles, and lipo K-ras represents antimutant K-ras siRNA transfected
using lipofectamine 2000. (c) MTT assay showing in vitro antiproliferative activity of antimutant K-ras siRNA nanoparticles in A549 cells, n = 5,
***P ≤ 0.001.
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Week 1
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Figure 2 SCID beige mice showing tumor burden in the lungs
and colorectal region over a 3-week period.
siRNA nanoparticles

20,000
Plasma concentration (ng/ml)

Naked siRNA
15,000

10,000

In vivo stability of siRNA
In vivo stability of siRNA delivered by anti-NTSR1-mAbfunctionalized hybrid nanoparticles was compared to that of
the naked siRNA using ion-pair HPLC-UV following siRNA
isolation using Clarity OTX, an oligonucleotide extraction cartridge (Phenomenex, Torrance, CA). Blood samples collected
by orbital puncture at 0-, 30-, and 90-minute and 24-, 25-,
26-, and 48-hour time points were analyzed for signs of degradation. The presence of single-stranded oligonucleotides in
the naked siRNA samples was observed immediately after
30 minutes of administration. However, degradation products
were not observed in the corresponding sample for hybrid
nanoparticle-delivered siRNA. Figure 5a demonstrates the
presence of single-stranded oligonucleotides as well as the
presence of higher molecular weight degradation products
in the naked siRNA samples, 25 hours after administration.
However, such degradation/metabolic products were not
observed in the corresponding hybrid nanoparticle-delivered
siRNA samples. The first sign of degradation in the hybrid
nanoparticle-delivered siRNA samples was not observed
until 48 hours postadministration. This confirms the ability of
the hybrid nanoparticles to protect the encapsulated siRNA
in vivo similar to what was observed in vitro.4
Discussion

5,000

0
0

1,000

2,000

3,000

4,000

Time (minutes)

Figure 3 siRNA plasma concentration over time. Tumor-bearing
mice were given a single dose of 0.9 mg/kg of antimutant K-ras
siRNA either in anti-NTSR1-mAb-functionalized nanoparticles or as
naked siRNA. n = 3.

nanoparticles for siRNA delivery in murine models of lung
cancer in comparison to the naked siRNA formulation.
Key pharmacokinetic parameters presented in Table 2 further demonstrate the superiority of using these novel antiNTSR1-mAb-functionalized hybrid nanoparticles for siRNA
delivery in murine models of lung cancer in comparison to
the naked siRNA formulation.
Tissue distribution of siRNA in NSCLC murine models
Figure 4 demonstrates the discriminatory delivery of siRNA
to tumor-bearing lungs by anti-NTSR1-mAb-functionalized
hybrid nanoparticles over a 3-day period. In contrast, naked
siRNA was not discriminatory in tissue delivery. After 5 hours,
a significant accumulation of siRNA delivered by anti-NTSR1mAb-functionalized hybrid nanoparticles was observed in
tumor-bearing lungs in comparison to the liver (P ≤ 0.05). On
the second day after siRNA administration, an even more significant accumulation in the lung tumor was observed when
compared to the kidneys (P ≤ 0.01). On the third day after
siRNA administration, total clearance was observed in the
liver, heart, and kidney, leaving the lung tissue as the only
tissue with siRNA accumulation.

This study presents the biodistribution and pharmacokinetics
properties of siRNA encapsulated in an anti-NTSR1-mAbfunctionalized hybrid nanoparticles in comparison to naked
siRNA. These hybrid nanoparticles combine the benefits
derived from human immunoglobulin G (human IgG) and
poloxamer-188 (polyoxyethylenepolyoxypropylene block
copolymer), for stable and efficient siRNA delivery. Human
IgG is the main antibody isotype found in blood, it is the main
immunoglobulin that protects the body against infection. Since
human IgG is part of the body’s natural defends mechanism,
we hypothesized that a nanoparticle composing IgG would
reduce the well-documented immunogenic reaction experienced with most nanoparticle formulations. This hypothesis
has been tested and proved to be correct.4 Poloxamer-188,
a nonionic triblock copolymer, has been previously used as
a stealth polymer to prevent macrophage uptake of nanoparticles hence circumventing the reticuloendothelial system
during systemic circulation. It was proposed that it reduces
opsonization by serum proteins hence reducing macrophageal uptake.9,10 The combination of these two components in
a single nanoparticle delivery system makes these nanoparticles quite unique. In this study, hybrid nanoparticles were
functionalized with anti-NTSR1-mAb to convert them into an
actively targeted nanoparticle delivery system for delivering
siRNAs to NSCLC cells using NTSR1 as a delivery target.
NTSR1 has been shown by immunohistochemistry to be
overexpressed in ~60% of lung adenocarcinoma.7 In early
stages of NSCLC, NTSR1 was one of the first 50 genes
upregulated and associated with disease-free survival.8 We
aimed to take advantage of this overexpression in NSCLC to
achieve an optimized targeting of siRNA to NSCLC by conjugating anti-NTSR1-mAb to the surface of our hybrid nanoparticles. Anti-NTSR1-mAb was attached to the nanoparticles to
www.moleculartherapy.org/mtna
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Figure 4 In vivo biodistribution studies. Biodistribution of antimutant K-ras siRNA following i.p. injection of siRNA in (a) functionalized
hybrid nanoparticles and (b) naked siRNA. Lung data statistically compared to the next highest accumulation in tissues of the same time point.
*P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. n = 3.
Table 2 Key pharmacokinetic parameters of naked siRNA and
siRNA-loaded anti-NTSR1-mAb-functionalized hybrid nanoparticles in
SCID models of metastatic orthotopic non-small-cell lung cancer
Parameters

Naked siRNA

siRNA nanoparticles

Cmax (ng/ml)

7504.9

17289.5

Tmax (hour)

0.5

1

AUClast (hour.ng/ml)

13393.88

454089.63

CL/F (ml/minute/kg)

1.1 × 10−6

2.9 × 10−8

λz (1/hour)

0.4490

0.0408

T1/2 (hour)

1.5

17.0

MRT (hour)

6.6

22.6

1.5 × 10−4

4.23 × 10−5

VZ/F (l/kg)

AUClast, area under the plasma concentration–time curve from time zero to
time of last measurable concentration; CL/F, apparent clearance; Cmax, peak
plasma concentration; MRT, mean residence time; T1/2, plasma terminal
half-life; Tmax, time to peak plasma concentration; VZ/F, apparent volume of
distribution; λz, elimination rate constant.

the preformed nanoparticles by thiolating anti-NTSR1-mAb
using 2-iminothiolane (Traut’s reagent) as reported previously.11,12 N-[p-maleimidophenyl] isocyanate was used as
a heterobifunctional, sulfhydryl and hydroxyl-reactive linker
and was conjugated to the hydroxyl groups present in poloxamer-188 on the surface of the hybrid nanoparticles.13 The
isocyanate end of N-[p-maleimidophenyl] isocyanate reacted
with the hydroxyl group on the nanoparticles to form carbamate linkage while the maleimide end reacted with the sulfhydryl groups in the thiolated anti-NTSR1.14 The particle size
of anti-NTSR1-mAb-functionalized nanoparticles was slightly
higher than the corresponding nonfunctionalized nanoparticles as shown in Table 1. Particle size, zeta potential, loading
efficiency, and encapsulation efficiency of hybrid nanoparticles presented in Table 1 have been previously reported by
our group.7 The increase in size may be attributed to the conjugation of mAb to the surface of the nanoparticles. Further,
the fact that several centrifugation steps and lyophilization
were involved in the conjugation process may also contribute
to the increase in particle size.12,13
Metastatic model of lung cancer developed in Figure 2
shows that tumor was initially implanted in the colorectal
region of the mice before finally metastasizing to the lung
rather than the commonly observed trend of initial implantation in the lungs before metastasis to other areas of the body.
Molecular Therapy—Nucleic Acids

This is because of the relatively lesser number (5 × 105) of
A549-luciferase cells injected into the tail vain of the mice.
Observations in our laboratory showed that when higher
number of cells such as 5 × 106 was injected into the tail vain,
initial implantation of tumor in the lung was observed.
One of the main limitations to the application of siRNA in
translational medicine is the fact that they are very vulnerable
to endonuclease enzymes found in body fluids.4 The rapid
clearance of naked siRNA from the blood of the mice could
be attributed to degradation by endonucleases in the blood.
However, the hybrid nanoparticle delivery system offered
protective armor to the siRNA when delivered using the antiNTSR1-mAb-functionalized hybrid nanoparticles, hence the
lower clearance rate. The protection of the siRNA by the
nanoparticle delivery system could also be responsible for
the longer plasma terminal half-life and the higher mean residence time in comparison to the naked siRNA formulation.
Figure 4 demonstrates that siRNA delivered using antiNTSR1-mAb-functionalized hybrid nanoparticles were
mostly accumulated in the lung after 5 hours. However, the
liver and the kidney also had substantial amount of siRNA
delivered at this time. The liver among other organs such as
spleen belong to the reticuloendothelial system organs.15
Liver is also a highly perfused organ; hence, nanoparticle
carriers are rapidly distributed to this organ.15,16 Further, the
microvessels of liver have relatively large fenestrations which
allow entry of particles as high as ~200 nm.17 In view of this,
systemically delivered nanoparticles usually accumulate in
the liver and spleen.17 The kidney also demonstrated a high
amount of siRNA probably because it is highly perfused and
it is the main organ for elimination. However, after 24 hours,
a more discriminatory delivery of siRNA to tumor-bearing
lungs began to manifest due to the effect of the presence
of anti-NTSR1-mAb on the hybrid nanoparticles coupled
with the fact that tumors are naturally more permeable to
the penetration of particles between 100 and 800 nm due
to enhanced permeation and retention effect.1,15 After 48
hours, siRNA from anti-NTSR1-mAb-functionalized hybrid
nanoparticles could only be seen in the tumor-bearing lung
and was completely cleared from other organs probably due
to the interaction between anti-NTSR1-mAb on the surface
of the nanoparticles and the NTSR1 receptors present in the
tumor-bearing lungs. Out of curiosity, we wanted to know if

Biodistribution and Pharmacokinetics Study
Perepelyuk et al.

5

a

0.0012
0.0011
0.0010
0.0009
0.0008

Intact DS siRNA

0.0007
0.0006

Single-stranded oligonucleotide

AU

0.0005
0.0004
0.0003
0.0002

High-molecular-weight
degradation product

0.0001
0.0000
−0.0001
−0.0002
−0.0003
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 7.50 8.00 8.50 9.00 9.50 10.00
Minutes

b

0.080
0.070
0.060

AU

0.050
0.040
0.030
0.020
0.010
0.000
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 7.50 8.00 8.50 9.00 9.50 10.00
Minutes

Figure 5 In vivo stability studies. High-performance liquid chromatogram of (a) naked siRNA and (b) hybrid nanoparticle-delivered siRNA
25 hours after i.p. administration to tumor-bearing mice. DS siRNA, double-stranded siRNA.

anti-NTSR1-mAb-functionalized nanoparticles were able to
deliver siRNA to metastasized tumor in the colorectal region.
Tumor in this area was harvested in some mice and analyzed
for siRNA delivery. A significant accumulation of siRNA was
detected in these metastasized tumors. In contrast, naked
siRNA formulation showed a conspicuous lack of selectivity
in the delivery of siRNA to tumor-bearing lungs and other
organs after 24 hours. Further, naked siRNA was also significantly cleared from the tumor-bearing lungs after 48 hours.
In conclusion, Anti-NTSR1-mAb-functionalized hybrid
nanoparticles were able to drive the pharmacokinetics and
biodistribution of siRNA in tumor-bearing mice. These nanocarriers were able to significantly reduce the clearance and
increase the circulation time of siRNA in plasma when compared to that of naked siRNA formulation. siRNA delivered
to anti-NTSR1-mAb-functionalized hybrid nanoparticles were
selectively delivered in tumor-bearing lungs over a period of

48 hours. Hybrid nanoparticles also protected encapsulated
siRNA from degradation in systemic circulation. Thus, these
novel hybrid nanoparticles can serve as an effective nonviral
vector for siRNA delivery.
Materials and methods
Chemicals and reagents. Human IgG was purchased from
Equitech Bio (TX). Poloxamer-188, RNase-free water, and
fetal bovine serum were obtained from Fisher Scientific.
siRNA against mutated K-ras G12S was designed and
purchased from Thermo Scientific (Rockford, IL; formerly
Dharmacon). siG12S sense and antisense sequences
are GUUGGAGCUAGUGGCGUAGdTdT and CUACGCCACUAGCUCCAACdTdT, respectively. Clarity OTX solidphase extraction was obtained from Phenomenex. Erlotinib
hydrochloride and HPLC grade solvents were purchased
www.moleculartherapy.org/mtna
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from Fisher Scientific (Pittsburgh, PA). XenoLight RediJect
D-Luciferin Bioluminescent Substrate was obtained from
Perkin Elmer (Waltham, MA). Mouse antineurotensin receptor 1 monoclonal antibody was purchased from Santa Cruz
Biotechnology (Dallas, TX). Monoclonal antibodies specific
for mutant G12S K-ras proteins was obtained from NewEast
Biosciences, King of Prussia, PA.
Cell culture. Human adenocarcinoma cell line A549-luciferase, expressing K-ras mutation at G12S, was obtained
from Perkin Elmer. They were maintained in F12K medium
supplemented with 10% fetal bovine serum and 1% antibiotics. They were kept in a humidified air atmosphere with 5%
carbon dioxide.
Western blot analysis. Cells were washed twice with icecold phosphate-buffered saline. Cell lysates were prepared
in Pierce RIPA buffer (Thermo Scientific) with addition of
Pierce Protease Inhibitor Mini Tablets (Thermo Scientific).
The protein concentration was determined with the Coomassie Plus (Bradford) Assay Kit (Thermo Scientific). About
80 µg of total proteins was separated on NuPAGE 4–12%
Bis-Tris gels (Life Technologies, Carlsbad, CA) with NuPAGE
MES SDS running buffer (Life Technologies) and subsequently transferred onto nitrocellulose membrane of 0.45 µm
pore size (Life Technologies). The membrane with proteins
was blocked according to manufacturer’s instructions (Invitrogen, Carlsbad, CA) for 1 hour at room temperature and
probed with primary antibodies—K-ras G12S monoclonal
antibody (1:500; New East Biosciences, Malvern, PA) and
β-actin (1:5,000; Sigma-Aldrich, St. Louis, MO) overnight at
4 °C. The membranes were washed three times for 5 minutes in wash buffer according to manufacturer’s instructions
(Invitrogen) and incubated with secondary goat anti-mouse
secondary antibodies, conjugated with horseradish peroxidase (Molecular Probes, Eugene, OR) at a dilution 1:1,000.
Immune complexes were detected with chemiluminescent
substrate, Pierce ECL Western Blotting Substrate (Thermo
Scientific) in a dark room on tabletop processor SRX-101A
(Konica Minolta, Japan). Images were quantified in the
ImageJ software.
Cytotoxicity assay. MTT assay was used to determine the
effect of siG12S-loaded nanoparticles on the proliferation of
A549 cells. Cells (1 × 104)/well were seeded in 96-well plates
and incubated at 37 °C in a humidified atmosphere with 5%
carbon dioxide for 24 hours. The cells were then treated with
different concentrations of siG12S-loaded hybrid nanoparticles and scramble-siRNA-loaded hybrid nanoparticles. Cells
were incubated for 72 hours. About 10 µl of 12 mmol/l MTT
reagent was then added to each well. This was then incubated at 37 °C for 4 hours. The medium was aspirated and
50 µl of sterile dimethyl sulfoxide was added to each well and
mixed thoroughly with pipet. The cells were then incubated at
37 °C for 10 minutes. The plate was read at 540 and 650 nm.
Animals. Female severe combined immunodeficient (SCID)
beige mice, 7–8 weeks old and weighing ~25 g were supplied by Taconic and maintained in the American Association for the Accreditation of Laboratory Animal Care
Molecular Therapy—Nucleic Acids

(AAALAC)-accredited facility at Thomas Jefferson University.
All animal studies were approved by the Institutional Animal
Care and Use Committee of Thomas Jefferson University.
Preparation of siRNA-loaded hybrid nanoparticles. Hybrid
nanoparticles were prepared based on our previously
reported protocol.4 About 50 mg of excipient-free human
IgG was dissolved in 0.01 N HCl containing 20 mg of poloxamer-188 and 187 µg of siRNA to make a 10 ml total solution
in a 50 ml beaker. The final concentration of human IgG in
each solution amounted to 5 mg/ml. This solution was then
slowly titrated with 0.01 N NaOH to bring the pH of the mixture to 7, which is the isoelectric point (pI) of human IgG as
determined in our laboratory using isoelectric focusing. The
nanoparticles were continuously mixed on a magnetic stirrer
for additional 10 minutes. At the pI, siRNA-loaded nanoparticles were spontaneously precipitated. The colloidal suspension was then centrifuged with a micro centrifuge (Eppendorf
centrifuge 5418) at 2,000 rpm for 5 minutes. The nanoparticles
were rinsed with double distilled deionized water before being
redispersed in water and snap-frozen using liquid nitrogen.
This was then loaded into a freeze-dryer (Labconco FreezeZone 4.6), and lyophilization was performed for 48 hours.
Thiolation of anti-NTSR1-mAb. Thiolation of anti-NTSR1mAb was performed based on a method adopted from a
previously used method.18 Briefly, 1.3 × 10−4 mol/l of Traut’s
reagent (2-Iminothiolane HCl) was prepared in phosphatebuffered saline (pH 7.4). Further, 500 µl of this solution was
then added to 1 ml of 1.3 × 10−6 mol/l (0.2 mg/ml) of antiNTSR1-mAb solution. The reaction was stirred for 2 hours at
25 °C. The mixture then centrifuged at 4,000 rpm and 10 °C
for 15 minutes using 30 kDa cutoff centrifugal ultrafilters (Millipore Corp.) to exclude unreacted Traut’s reagent.
Activation of hybrid nanoparticles with heterobifunctional
cross-linker. About 5 mg/ml of hybrid nanoparticles were
dispersed in 0.1 mol/l phosphate buffer (pH 7.2). This was
then added to 2 mg/ml of N-[p-maleimidophenyl] isocyanate, a heterobifunctional cross-linker that links sulfhydryl
to hydroxyl groups.10 N-[p-maleimidophenyl] isocyanate was
dissolved in 50 mmol/l phosphate buffer (pH 8).The reaction
was performed for 3 hours at 25 °C, after which the activated
nanoparticles were centrifuged at 4,000 rpm at 10 °C for 15
minutes using 30 kDa ultrafilters (Millipore Corp.).
Preparation of anti-NTSR1-mAb-functionalized hybrid nano
particles. The activated nanoparticles were finally functionalized with the thiolated anti-NTSR1-mAb by adding 500 µl
of 2 mg/ml thiolated anti-NTSR1-mAb to 4 ml of activated
nanoparticle suspension (5 mg/ml) and then incubated for
3 hours at 25 °C. The functionalized nanoparticles were then
centrifuged for 30 minutes at 4,000 rpm and 10 °C. Unconjugated anti-NTSR1-mAb in the supernatant was quantified
using Total Protein Kit (Micro Lowry, Sigma) based on the
supplier’s instructions.
Nanoparticle characterization. Photon correlation spectroscopy using ZetaSizer Nano ZS (Malvern Instruments, UK)
was used to measure the particle size and zeta potential of
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Figure 6. Schematic of the siRNA isolation protocol using
Clarity OTX. HPLC, high-performance liquid chromatography.

the nanoparticles. Pellets were redispersed in deionized water
and sonicated for ~5 minutes. Intensity autocorrelation was
measured at a scattering angle (θ) of 173°. The Z-average
and polydispersity index were recorded in triplicate. For zeta
potential, samples were taken in a universal dip cell (Malvern
Instruments) and the zeta potential recorded in triplicate.
The morphology of nanoparticles was obtained using
scanning electron microscopy. Powder was layered on a
scanning electron microscopy stub and spread gently using
a spatula. Samples were then coated with a thin layer of palladium. Coated samples were imaged using a Zeiss Supra
50 V system (Zeiss, Jena, Germany).
Murine models of metastatic NSCLC. Metastatic models of
NSCLC were created by injecting 5 × 105 A549-luciferase
cells suspended in sterile phosphate-buffered saline into the
tail veins of SCID beige mice. Tumor burden was monitored
using Xenogen IVIS bioluminescence imaging system. About
100 µl of 30 mg/ml Xenolight Rediject D-Luciferin was administered by i.p. injection into the mice ~10 minutes before animals were imaged.
Animal treatment and blood sampling. Tumor-bearing mice
were divided into two groups. The first group was treated
with a single dose of 0.9 mg/ml siRNA loaded into antiNTSR1-mAb-functionalized hybrid nanoparticles while the
second group was treated with 0.9 mg/ml naked siRNA. Both
nanoparticles and naked siRNA were dispersed in sterile
phosphate-buffered saline. Blood samples were collected
from three mice per group per time point at 0, 30, and 60 minutes and 24, 25, 26, and 48 hours post-dose by retro-orbital
puncture into ethylenediaminetetraacetic acid tubes. Animals
were also sacrificed on days 1, 2, and 3 to harvest the lungs,
kidneys, heart, and livers for analysis. Blood samples were
mixed with equal amount of lysis-loading buffer of Clarity
OTX kit (Phenomenex, CA) and stored at −80 °C until ready
to be used. Tissues were snap-frozen in the liquid nitrogen
stored at −80 °C before analysis.
siRNA isolation and ion-pair HPLC. siRNA in blood and tissue
was isolated for HPLC using Clarity OTX kit (Phenomenex)
with Thermo Scientific HyperSep Vacuum Manifold (Thermo
Sci National Scientific, Rockwood, TN) according to manufacturer’s instructions. Briefly, equal aliquots of Clarity OTX
loading buffer was mixed with plasma samples prior to loading on the solid-phase extraction cartridge. Solid-phase
extraction isolation cartridge (Clarity OTX 100 mg/3 ml: Phenomenex) was first wetted with methanol before equilibrating

with Clarity equilibration buffer (10 mmol/l phosphate, pH 5.5)
before sample loading. For tissue samples, they were first
homogenized in 0.1 mol/l Tris buffer, pH 8.0 and then mixed
with equal amount of lysis-loading buffer. After sample loading, equilibration buffer was added to the cartridge to rinse
twice before rinses with Clarity OTX wash buffer (10 mmol/l
phosphate, pH 5.5/50% acetonitrile). Elution buffer (100
mmol/l ammonium bicarbonate, pH 8.0/40% acetonitrile/10%
tetrahydrofuran) was then added to elute the siRNA from the
cartridge. Samples were then speed vacuum evaporated to
100 µl before liquid chromatography analysis.
Figure 6 shows the schematic of the siRNA isolation protocol. SiRNA was analyzed using a well-validated ion-pair
HPLC method.4,19,20 Briefly, analysis was performed using an
Alliance HPLC system, Waters 2695 Separation Module combined with a Water 2998 photodiode array detector (Waters,
Milford, MA). A Clarity 3 µm Oligo-RP column (Phenomenex)
with column dimension 50 × 2.0 mm was used. One microliter
of siRNA sample was injected using 20 mmol/l triethylamineacetic acid (pH 7) and 5–12% acetonitrile, gradient elusion
as mobile phase. Analysis was performed at a flow rate of
0.2 ml/minute. UV detection was performed at 269 nm and
chromatogram was recorded using Empower Prosoftware.
Pharmacokinetic data analysis. Pharmacokinetic parameters
were estimated using noncompartment analysis of the composite data with WinNonlin software version 6.0 (Pharsight,
Mountain View, CA).
Statistical analysis. Results are expressed as mean ± SD,
unless otherwise indicated. Statistically significant difference
between two groups was determined by two-tailed Student’s
t-test. A P value of 0.005 was taken as statistically significant.
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